Abstract： Objective： To observe the clinical effect of Weili Capsules combined with Hydrotalcite Tablets on bile reflux gastritis (BRG) with gallbladder- stomach disharmony syndrome and its effect on levels of gastrointestinal hormones and inflammatory indexes of patients. Methods：A total of 150 patients with BRG with gallbladder-stomach disharmony syndrome were selected and divided into the control group and the observation group，with 75 cases in each group. The control group was treated with Hydrotalcite Tablets， and the observation group was additionally given Weili Capsules based on the treatment of the control group. Both groups were treated for 4 weeks. The clinical effects， classification of bile reflux， scores of gastric mucosal inflammation，Quality of Life Instruments for Chronic Disease- Chronic Gastritis (QLICD- CG V2.0) and symptoms，and levels of gastrointestinal hormones and inflammatory indexes were compared between the two groups，the adverse reactions were observed. Results：After treatment，the total clinical effective rate was 90.67% in the observation group，higher than that of 76.00% in the control group (P＜0.05). The degree of bile reflux in both groups were lessened when compared with those before treatment (P＜0.05)，and the release of the degree of bile reflux in the observation group was more obvious than that in the control group (P＜0.05). The scores of gastric mucosal inflammation in the two groups were decreased when compared with those before treatment (P＜0.05)，and the QLICD- CG V2.0 scores were increased when compared with those before treatment (P＜0.05)； the score of gastric mucosal inflammation in the observation group was lower than that in the control group (P＜0.05)，and the QLICDCG V2.0 score was higher than that in the control group (P＜0.05). The scores of abdominal pain，abdominal swelling，nausea and vomiting，and bitter mouth in the two groups were decreased when compared with those before treatment (P＜0.05)，and the above 4 scores in the observation group were lower than those in the control group (P＜0.05). The levels of motilin (MTL) in plasma in both groups were increased when compared with those before treatment (P＜0.05)， and levels of gastrin (GAS)， cholecystokinin (CCK)， tumor necrosis factor-α (TNF-α)，monocyte chemotactic protein-1 (MCP-1)，and interleukin-1β (IL-1β) in serum were decreased when compared with those before treatment (P＜0.05)； the level of MTL in plasma in the observation group was higher than that in the control group (P＜0.05)，and the levels of GAS， CCK，TNF-α，MCP-1，and IL-1β in serum were lower than those in the control group (P＜0.05). During treatment， no obvious adverse reactions occurred in the two groups. Conclusion： Weili Capsules combined with Hydrotalcite Tablets can safely and effectively mitigate the clinical symptoms of BRG patients with gallbladder- stomach disharmony syndrome， inhibit the bile reflux， reduce the gastric mucosal inflammation presented in the endoscope，and enhance the quality of life of patients.